B. Riley Securities maintains Agenus at Buy, raises price target to $16 from $14

B. Riley Securities kept its Buy rating on Agenus and increased its price target to $16 from $14, suggesting a 123.8% upside from the Nov 6 close of $7.15.

Original reporting
Published Nov 9, 2026, 2:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
B. Riley Securities maintains Agenus at Buy, raises price target to $16 from $14 — source image
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The higher target may attract new buying interest and support the stock price.

02

Market read

A modest analyst upgrade that could provide short‑term upside for traders.

03

What to watch

Potential regulatory or trial setbacks not reflected in the rating.

Relevance 5/10Novelty 5/10Timing: immediate

Background

Analyst rating maintenance with an upgraded price target.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

B. Riley raised Agenus price target to $16 from $14, indicating a bullish outlook.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

Target increase reflects improved expectations; no immediate catalyst beyond the rating change.

Market effects

May lift sentiment in the biotech sector as analysts show confidence in Agenus.

Limited to U.S. biotech investors.

Minimal global impact beyond niche biotech investors.

Counterpoint

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • Agenus Inc.

    Biotech firm focused on immuno-oncology.

  • B. Riley Securities

    Equity research analyst raising Agenus target.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.